Labiotech.eu

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 27 Sep 2022

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Approval of an investigational new drug (IND) application for mupadolimab has been granted by the Center for Drug Evaluation (CDE) to initiate a phase 1/1b clinical trial in China. Angel Pharma, a clinical stage biopharmaceutical company owns the rights to mupadolimab in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73. In preclinical […]

September 27, 2022 - 2 minutesmins - By Liza Laws

Interview 27 Sep 2022

Europe’s first lab-grown fish company Bluu Seafood is aiming for sustainability

Overfishing is a global issue that negatively impacts the ecosystem and our access to fish protein. One solution to overfishing is producing fish products in the lab from harvested animal cells. This can help feed the world while using up fewer resources and without endangering wild fish populations. As the world’s population continues to grow, […]

September 27, 2022 - 5 minutesmins - By Omnia Ibrahim

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […]

September 27, 2022 - 6 minutesmins - By External Contributor

News and Trends 26 Sep 2022

Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke

The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke. Acticor Biotech, a clinical stage biotech company, made the announcement today (September 26). The patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by neurologist, Ruchir Shah. Significant potential He said: “I am very […]

September 26, 2022 - 3 minutesmins - By Liza Laws

CEO and founder Bjorn Manuel Hegelich aligning laser beams within a laser system at TAU's facility in Austin, Texas.

News and Trends 26 Sep 2022

TAU Systems to build new generation of compact particle accelerators after $15M investment

TAU Systems has raised $15 million in seed investment to bring particle accelerators to a multitude of users by harnessing the latest laser technology to make electrons surf on three-dimensional plasma waves and accelerate them to ultra-high energies. The news is significant as, until now, high-energy particle accelerators have been limited to countries and governmental […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […]

September 26, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Commercial launch of monkeypox PCR test for research use in laboratories worldwide

A newly developed molecular polymerase chain reaction (PCR) test for monkeypox is now commercially available globally for research use only applications. Becton, Dickinson and Company (BD) and CerTest Biotec made the announcement today (September 26) that the test can be used in laboratories. The teams leveraged the BD MAX System open architecture reagent suite to develop […]

September 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

A toxicology facility with more than 10,000 sq ft of laboratory space has opened in Australia and will help Agilex Biolabs expand its capacity to serve the biotech, pharma and animal health industries. After more than 25 years in the industry, Agilex Biolabs says it will now be able to share with an even more […]

September 26, 2022 - 2 minutesmins - By Liza Laws

Interview 26 Sep 2022

Rapid diagnostics are needed to tackle antimicrobial resistance

As the antimicrobial resistance (AMR) crisis grows, bacterial infections are becoming harder to treat. Chris Lock, vice president of R&D at the mass spectrometry specialist SCIEX, discusses how rapid diagnostics can help doctors wield antimicrobial treatments more effectively. The AMR crisis is growing increasingly severe, resulting in superbugs that are able to shrug off multiple […]

September 26, 2022 - 5 minutesmins - By Jonathan Smith

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 26 Sep 2022

Surge raises $2.6M in funding for technology and secures exclusive licensing agreement

Surge, a biotech and artificial intelligence innovator that produces technology to decode immune fingerprints, has received $2.6 million in funding. The technology accurately identifies patients at risk before surgery and enables physicians to quickly forecast the risk of postoperative complications. The funding round was co-led by HCVC, a global early-stage fund dedicated to high-potential […]

September 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

Kupando raises €13M in series A funding round led by Remiges Ventures

A company developing agonists that stimulate immune cells today (September 26) announced it has secured €13 million ($12.6 million) in series A funding. Germany-based Kupando develops TLR/47 that stimulate innate immunity for use in oncology and infectious diseases. Kupando says it will use the funds to complete IND-enabling work and to initiate the clinical development […]

September 26, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Natural killer cells: a thriving frontier in allogeneic cell therapy

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Europe’s first lab-grown fish company Bluu Seafood is aiming for sustainability

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke

TAU Systems to build new generation of compact particle accelerators after $15M investment

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

Commercial launch of monkeypox PCR test for research use in laboratories worldwide

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

Rapid diagnostics are needed to tackle antimicrobial resistance

Surge raises $2.6M in funding for technology and secures exclusive licensing agreement

Kupando raises €13M in series A funding round led by Remiges Ventures

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!